3003新葡的京集团

	SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (09989)

► Cover ► Important ► Expected Timetable ► Contents ► Summary ► Definitions ► Glossary of Technical Terms ► Forward-looking Statements ► Risk Factors ► Waivers and Consents from Strict Compliance with the Hong Kong Listing Rules ► Information about this Prospectus and the Global Offering ► Directors, Supervisors and Parties Involved in the Global Offering ► Corporate Information ► Industry Overview ► Regulatory Environment ► History, Development and Corporate Structure ► Business ► Relationship with the Controlling Shareholders ► Connected Transaction ► Directors, Supervisors and Senior Management ► Share Capital ► Substantial Shareholders ► Cornerstone Investors ► Financial Information ► Future Plans and Use of Proceeds ► Underwriting ► Structure of the Global Offering ► How to Apply for the Hong Kong Offer Shares ► Appendix I - Accountants' Report ► Appendix IA - Report on Review of Interim Condensed Consolidated Financial Information for the Three Months Ended March 31, 2020 ► Appendix II - Unaudited Pro Forma Financial Information ► Appendix III - Taxation and Foreign Exchange ► Appendix IV - Summary of Principal Legal and Regulatory Provisions ► Appendix V - Summary of Articles of Association ► Appendix VI - Statutory and General Information ► Appendix VII - Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection ► Back Cover